ReviewPathologica2021
Multicentric Castleman disease and the evolution of the concept.
Review in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Study of Bone Marrow Findings in Human Immunodeficiency Virus (HIV) Positive Patients in a Tertiary Care Hospital.Cardiovascular & hematological disorders drug targets · 2026Article
- Unilateral Renal Castleman Disease Presenting with Acute Abdominal Pain: A Case Report and Literature ReviewCurrent medical imaging · 2026Review
- Exploring castleman disease in a cohort of hispanic patients: a recognition to its histopathology.Journal of hematopathology · 2025Article
- Article
- When cytokine storms collide: understanding hemophagocytic lymphohistiocytosis in human herpesvirus 8/Kaposi sarcoma herpesvirus-associated multicentric Castleman disease among people with HIV.AIDS (London, England) · 2025Article
- Molecular Mechanisms of Kaposi Sarcoma-Associated Herpesvirus (HHV8)-Related Lymphomagenesis.Cancers · 2024Review
- Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy.Blood vessels, thrombosis & hemostasis · 2024Article
- Stroma-Rich Hyaline Vascular Type of Castleman Disease: A Case Report and Literature Review.Cureus · 2024Article
- Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting.Open forum infectious diseases · 2024Review
- A Case of Castleman's Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium.Diagnostics (Basel, Switzerland) · 2024Article
- Retrospective cohort evaluation of non-HIV Castleman disease from a single academic center in Beijing, China.Annals of hematology · 2024Article
- A Rare Case of Orbital Castleman Disease with Overlapping IgG4-Related Disease.Medicina (Kaunas, Lithuania) · 2023Article
- Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.Rheumatology (Oxford, England) · 2023Review
- A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions.British journal of haematology · 2023Article
- Hyaline Vascular Type of Unicentric Castleman Disease in a Kidney with End-Stage Renal Disease: A Case Report of a Rare Entity at an Unusual Location and a Special Clinical Setting.Diagnostics (Basel, Switzerland) · 2022Article
- Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980.Journal of clinical and experimental hematopathology : JCEH · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term multicentric Castleman disease (MCD) encompasses a spectrum of conditions that share some overlapping clinicopathological manifestations. The fundamental pathogenetic mechanism involves dysregulated cytokine activity, causing systemic inflammatory symptoms as well as lymphadenopathy. Some of the histological changes in lymph nodes resemble the histology of unicentric Castleman disease (UCD). However, based on current knowledge, the use of this shared nomenclature is unfortunate, since these disorders differ in pathogenesis and prognosis. In Kaposi sarcoma-associated herpesvirus (KSHV)-associated MCD, cytokine overactivity is caused by viral products, which can also lead to atypical lymphoproliferations and potential progression to lymphoma. In idiopathic MCD, the hypercytokinemia can result from various mechanisms, which ultimately lead to different constellations of clinical presentations and varied pathology in lymphoid tissues. The authors review the evolving concepts and definitions of the various conditions under the eponym of multicentric Castleman disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.